Cargando…
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
Tregs are able of suppressing tumor-specific effector cells, such as lymphocytes CD8+, CD4+ and Natural Killer cells. Different drugs, especially different schedules of administration, like metronomic chemotherapy (mCHT), seem to be able to increase anticancer immunity, by acting on downregulation o...
Autores principales: | Pepe, F. F., Cazzaniga, M. E., Baroni, S., Riva, F., Cicchiello, F., Capici, S., Cogliati, V., Maggioni, C., Cordani, N., Cerrito, M. G., Malandrin, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446532/ https://www.ncbi.nlm.nih.gov/pubmed/36068484 http://dx.doi.org/10.1186/s12885-022-10031-6 |
Ejemplares similares
-
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
por: Cazzaniga, M. E., et al.
Publicado: (2016) -
Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021) -
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
por: Trevisan, B., et al.
Publicado: (2023) -
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022) -
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)